# High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement

> **NCT00801216** · PHASE2 · COMPLETED · sponsor: **Andrés José Maria Ferreri** · enrollment: 40 (actual)

## Conditions studied

- B-cell Lymphomas

## Interventions

- **DRUG:** High-dose sequential chemotherapy and autologous transplant

## Key facts

- **NCT ID:** NCT00801216
- **Lead sponsor:** Andrés José Maria Ferreri
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801216, "High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00801216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*